185 related articles for article (PubMed ID: 27546593)
1. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
[TBL] [Abstract][Full Text] [Related]
2. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
3. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
4. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
[TBL] [Abstract][Full Text] [Related]
6. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
7. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
8. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profiling reveals key metabolic features of renal cell carcinoma.
Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S
J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817
[TBL] [Abstract][Full Text] [Related]
10. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
11. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
DiNatale RG; Sanchez A; Hakimi AA; Reznik E
Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
[TBL] [Abstract][Full Text] [Related]
13. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
14. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
18. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
19. [Metabonome in Early Diagnosis of Renal Cell Carcinoma].
Wang Z; Zhang YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):709-713. PubMed ID: 31699205
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]